Patient-reported outcomes in KEYNOTE-087, a phase 2 study of pembrolizumab in patients with classical Hodgkin lymphoma.

导出 LinkOut

翻译打印收藏纠错

第一作者： Bastian,von Tresckow

第一单位： Department I of Internal Medicine, University of Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany.

作者： Bastian,von Tresckow ^[1] ; Michelle,Fanale ^[2] ; Kirit M,Ardeshna ^[3] ; Robert,Chen ^[4] ; Julia,Meissner ^[5] ; Franck,Morschhauser ^[6] ; Craig,Moskowitz ^[7] ; Pier Luigi,Zinzani ^[8] ; Hilde,Giezek ^[9] ; Arun,Balakumaran ^[10] ; Thao T,Vo ^[10] ; Monika,Raut ^[10] ; Pauline,Brice ^[11]

作者单位： Department I of Internal Medicine, University of Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany. ^[1] Department of Lymphoma and Myeloma, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA. ^[2] University College London Hospitals, London, UK. ^[3] Department of Hematology, City of Hope National Medical Center, Duarte, CA, USA. ^[4] Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany. ^[5] CHRU Lille - Hopital Claude Huriez, Lille, France. ^[6] Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA. ^[7] Institute of Hematology 'L. e A. Seràgnoli', University of Bologna, Bologna, Italy. ^[8] MSD, Brussels, Belgium. ^[9] Merck & Co., Inc, Kenilworth, NJ, USA. ^[10] Hematology Department, AP-HP Hopital Saint-Louis, Paris, France. ^[11]

关键词 Classical Hodgkin lymphoma KEYNOTE-087 health-related quality-of-life patient-reported outcomes pembrolizumab